高危前列腺癌患者根治性前列腺切除术前行新辅助化疗的系统评价
Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review.
作者信息
Sfoungaristos Stavros, Kourmpetis Vasileios, Fokaefs Eleftherios, Perimenis Petros
机构信息
Department of Urology, Patras University Hospital, 26500 Patras, Greece.
出版信息
Chemother Res Pract. 2013;2013:386809. doi: 10.1155/2013/386809. Epub 2013 Feb 21.
Abstract
High-risk prostate cancer represents a pretentious clinical problem since a significant number of its patients will relapse and progress after radical prostatectomy. Neoadjuvant chemotherapy may be valuable since its efficacy in hormone-resistant prostate cancer has been established. In this paper, we report studies of neoadjuvant chemotherapies that have been used in high-risk patients prior to radical prostatectomy. Even though the results regarding the prognostic surrogates are not significant, the effects on clinical and pathological outcomes are promising, while toxicity in most of the studies is in the expected field.
摘要
高危前列腺癌是一个棘手的临床问题，因为大量此类患者在根治性前列腺切除术后会复发和进展。新辅助化疗可能具有重要价值，因为其在激素抵抗性前列腺癌中的疗效已得到证实。在本文中，我们报告了在根治性前列腺切除术之前用于高危患者的新辅助化疗研究。尽管关于预后替代指标的结果并不显著，但对临床和病理结果的影响很有前景，而在大多数研究中，毒性处于预期范围内。
相似文献
1
Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review.
Chemother Res Pract. 2013;2013:386809. doi: 10.1155/2013/386809. Epub 2013 Feb 21.
2
A systematic review of the role of adjuvant and neoadjuvant pharmacotherapy in patients undergoing radical prostatectomy.
Expert Opin Pharmacother. 2012 Jul;13(10):1421-36. doi: 10.1517/14656566.2012.690398. Epub 2012 May 30.
3
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Urology. 2003 Dec 29;62 Suppl 1:55-62. doi: 10.1016/j.urology.2003.09.052.
4
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
J Urol. 2009 Apr;181(4):1672-7; discussion 1677. doi: 10.1016/j.juro.2008.11.121. Epub 2009 Feb 23.
5
Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
BJU Int. 2007 Aug;100(2):274-80. doi: 10.1111/j.1464-410X.2007.06760.x. Epub 2007 Mar 12.
6
7
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Urology. 1997 Mar;49(3A Suppl):65-9. doi: 10.1016/s0090-4295(97)00171-4.
8
Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out.
Eur Urol. 2001;39 Suppl 1:10-4. doi: 10.1159/000052544.
9
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
J Clin Oncol. 2008 Oct 20;26(30):4928-33. doi: 10.1200/JCO.2007.15.0441. Epub 2008 Sep 15.
10
[Impact of androgen deprivation prior to radical prostatectomy for T1, T2 prostate cancer on the likelihood of curative surgery].
Nihon Hinyokika Gakkai Zasshi. 1997 Nov;88(11):936-44. doi: 10.5980/jpnjurol1989.88.936.
引用本文的文献
1
Head-to-head comparisons of [Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1240-1251. doi: 10.1007/s00259-022-06047-6. Epub 2022 Nov 22.
本文引用的文献
1
A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis.
Urology. 2012 Aug;80(2):484.e17-22. doi: 10.1016/j.urology.2012.02.027. Epub 2012 Apr 13.
2
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26.
3
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
4
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
World J Surg Oncol. 2012 Jan 4;10:1. doi: 10.1186/1477-7819-10-1.
5
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
J Urol. 2011 Sep;186(3):882-7. doi: 10.1016/j.juro.2011.04.087. Epub 2011 Jul 24.
6
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.
7
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.
8
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Cancer. 2010 Apr 1;116(7):1699-708. doi: 10.1002/cncr.24960.
9
Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Urol Oncol. 2011 Nov-Dec;29(6):608-13. doi: 10.1016/j.urolonc.2009.09.012. Epub 2009 Dec 21.
10
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.
Br J Cancer. 2009 Oct 20;101(8):1248-52. doi: 10.1038/sj.bjc.6605320. Epub 2009 Sep 15.
Zotero 插件